All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

VCN-01 Plus Chemo Improves Survival in Newly Diagnosed Metastatic Pancreatic Cancer

May 7th 2025

The addition of VCN-01 to gemcitabine and nab-paclitaxel improved survival in newly diagnosed metastatic pancreatic cancer.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

RAS(ON) Inhibitors May Overcome Resistance to Traditional KRAS Inhibitors in Solid Tumors

May 7th 2025

Study investigators are aiming to leverage therapy resistance, particularly in patients with solid tumors after receiving available RAS inhibitors.

Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC

May 7th 2025

Ultra-low PSA responses were linked with prolonged rPFS and delayed times to mCRPC and PSA progression for patients with mHSPC treated with darolutamide.

Pooled Analysis Shows POD24 Strongly Predicts Poor Survival in Newly Diagnosed MCL

May 6th 2025

Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.

NIAGARA Trial Validates Perioperative Durvalumab Approach in MIBC

May 6th 2025

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

First-Line Elraglusib Plus Chemo Improves Survival in Metastatic Pancreatic Cancer

May 6th 2025

The addition of elraglusib to gemcitabine and nab-paclitaxel improved overall survival is first-line metastatic pancreatic cancer.

Hackensack Meridian Health Expands Cancer Services with New Facility at JFK University Medical Center

May 6th 2025

Hackensack Meridian JFK University Medical Center has expanded its comprehensive cancer care services with the opening of a newly renovated, four-story facility at 80 James Street in Edison, NJ

FDA Grants Fast Track Designation to Givinostat for Polycythemia Vera

May 6th 2025

The FDA has granted fast-track designation to givinostat for the treatment of patients with polycythemia vera.

Acalabrutinib Plus BR Wins EU Approval for Previously Untreated, Transplant-Ineligible Mantle Cell Lymphoma

May 6th 2025

The European Commission has approved acalabrutinib plus bendamustine and rituximab for previously untreated, transplant-ineligible mantle cell lymphoma.

DUO-E Post Hoc Analysis Suggests Potential for Biomarker-Optimized pMMR Endometrial Cancer Management

May 6th 2025

Shannon Westin, MD, MPH, FACOG, contextualizes data from an exploratory biomarker analysis of the phase 3 DUO-E trial in pMMR recurrent endometrial cancer.

New ADCs Aim to Strengthen the HER2+ Breast Cancer Paradigm and Join T-DXd and T-DM1

May 6th 2025

The next-generation ADC ARX788 is under investigation in the phase 2 ACE-Breast-03 trial of patients with T-DXd–pretreated HER2-positive breast cancer.

Botensilimab Plus Balstilimab Elicits Durable Responses in Treatment-Refractory HCC

May 6th 2025

Phase 1 data support further exploration of botensilimab plus balstilimab in patients with hepatocellular carcinoma.

Nivolumab/Ipilimumab Meets Primary OS End Point in Non–Clear Cell RCC

May 5th 2025

The combination of nivolumab and ipilimumab was associated with longer 12-month OS vs standard of care in non–clear cell renal cell carcinoma.

Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small Cell Lung and Other Neuroendocrine Cancers

May 5th 2025

The DLL3- and CD3-targeted BiTE obrixtamig is being evaluated in patients with SCLC and other neuroendocrine cancers in the phase 2 DAREON-5 study.

Dana-Farber Launches the Ning Zhao & Ge Li Simulation Center to Develop and Train the Next Generation of Oncology Nurses

May 5th 2025

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept sBLA in BCG-Unresponsive Papillary NMIBC

May 5th 2025

A meeting has been requested to address the FDA's refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.

Frontline Eftilagimod Alpha/Pembrolizumab Yields Favorable OS in PD-L1–Negative HNSCC

May 5th 2025

Treatment with eftilagimod alpha plus pembrolizumab produced a median OS of 17.6 months in the first line for patients with PD-L1–negative HNSCC.

FDA Grants Fast Track Designation to ISB 2001 in Relapsed/Refractory Multiple Myeloma

May 5th 2025

ISB 2001 has received fast track designation from the FDA for patients with relapsed or refractory multiple myeloma who received 3 or more prior therapies.

Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm

May 5th 2025

Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.